Oncotarget

Research Papers:

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1

Zoran Gatalica, _ Nurija Bilalovic, Juan P. Palazzo, Ryan P. Bender, Jeffrey Swensen, Sherri Z. Millis, Semir Vranic, Daniel Von Hoff, Robert J. Arceci

PDF |  HTML  |  Author Information  |  Order a Reprint

 

Metrics: PDF 810 views  |   HTML 922 views  |   ?  

here


Abstract

Zoran Gatalica1, Nurija Bilalovic2, Juan P. Palazzo3, Ryan P. Bender1, Jeffrey Swensen1, Sherri Z. Millis1, Semir Vranic2, Daniel Von Hoff4 and Robert J. Arceci5

1 Caris Life Sciences, Phoenix, Arizona, USA

2 Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

3 Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Philadelphia, Pennsylvania, USA

4 Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona, USA

5 Department of Child Health, University of Arizona College of Medicine, Phoenix, Ronald Matricaria Institute of Molecular Medicine at Phoenix Children’s Hospital, Phoenix, Arizona, USA

Correspondence to:

Zoran Gatalica, email:

Keywords: histiocytoses, biomarkers, sequencing, targeted therapy, immunotherapy

Received: May 22, 2015 Accepted: May 29, 2015 Published: June 08, 2015

Abstract

The histiocytoses are rare tumors characterized by the primary accumulation and tissue infiltration of histiocytes and dendritic cells. Identification of the activating BRAFV600E mutation in Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) cases provided the basis for the treatment with BRAF and/or MEK inhibitors, but additional treatment options are needed. Twenty-four cases of neoplastic histiocytic diseases [11 extrapulmonary LCH, 4 ECD, 4 extranodal Rosai-Dorfman disease (RDD), 3 follicular dendritic cell sarcoma (FDCS), 1 histiocytic sarcoma (HS) and 1 blastic plasmacytoid dendritic cell neoplasm (BPDCN)] were analyzed using immunohistochemical and mutational analysis in search of biomarkers for targeted therapy. BRAF V600E mutations were detected in 4/11 LCH and 4/4 ECD cases. A pathogenic PTEN gene mutation and loss of PTEN protein expression were identified in the case of HS. Increased expression of PD-L1 (≥2+/≥5%) was seen in 3/4 ECD, 7/8 LCH, 3/3 FDCS and 1/1 HS, with overall 81% concordance between 2 antibodies used in the study (SP142 vs. MAB1561 clone). These results show for the first time significant expression of the PD-L1 immune checkpoint protein in these disorders, which may provide rationale for addition of immune check-point inhibitors in treatment of disseminated and/or refractory histiocytoses.

Author Information

Zoran Gatalica
Primary Contact  _

Nurija Bilalovic

Juan P. Palazzo

Ryan P. Bender

Jeffrey Swensen

Sherri Z. Millis

Semir Vranic

Daniel Von Hoff

Robert J. Arceci


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4378